SCHEMBL4969554

SCHEMBL4969554

CCCCCCCC(=O)N(C)Cc1cccc(-c2ccc(/C=C/C(=O)OC)c(OCc3ccccc3)c2)c1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HDAC8 Q9BY41 1/20 0.46
PTGER4 P35408 4/20 0.42
PTGER2 P43116 4/20 0.42
PTGER3 P43115 3/20 0.42
PTGER1 P34995 2/20 0.42
LTB4R Q15722 4/20 0.42
LTB4R2 Q9NPC1 4/20 0.42
PLA2G2D Q9UNK4 1/20 0.42
BACE1 P56817 1/20 0.41
AOC3 Q16853 3/20 0.41
MAP3K7 O43318 1/20 0.40
TAB1 Q15750 1/20 0.40
KDM4E B2RXH2 1/20 0.39
LMNA P02545 1/20 0.39
ALOX5 P09917 1/20 0.38
PSEN1 P49768 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4969557 1.00 HDAC8 (0.46) HDAC8PTGER4PTGER2PTGER3PTGER1
SCHEMBL4969336 0.94 PTGER4 (0.48) HDAC8PTGER4PTGER2PTGER3PTGER1
SCHEMBL4969332 0.94 PTGER4 (0.48) HDAC8PTGER4PTGER2PTGER3PTGER1
SCHEMBL4969981 0.86 AOC3 (0.41) LTB4R2AOC3
SCHEMBL4969978 0.86 AOC3 (0.41) LTB4R2AOC3
SCHEMBL4969846 0.79 AOC3 (0.46) LTB4R2AOC3
SCHEMBL4969850 0.79 AOC3 (0.46) LTB4R2AOC3
SCHEMBL4969521 0.79 PTGER4 (0.47) PTGER4PTGER2PTGER3PTGER1LTB4R
SCHEMBL5654914 0.79 KDM4E (0.55) PTGER4PTGER2PTGER3PTGER1LTB4R
SCHEMBL5654907 0.79 KDM4E (0.55) PTGER4PTGER2PTGER3PTGER1LTB4R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1781274-B1 NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE RECEPTORS OF PPAR TYPE AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS GALDERMA RES & DEV (FR) 2008-11-05 EP disclosed
US-20070207175-A1 Biaromatic compound activators of PPARgamma receptors and cosmetic/pharmaceutical compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2007-09-06 US disclosed
EP-1781274-A1 NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE RECEPTORS OF PPAR TYPE AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS Galderma Research & Development, S.N.C. (FR) 2007-05-09 EP disclosed
WO-2006018325-A1 NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE RECEPTORS OF PPAR TYPE AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070207175-A1 Biaromatic compound activators of PPARgamma receptors and cosmetic/pharmaceutical compositions comprised thereof PPARG, PPARA, PPARD HDAC8 415/4885PTGER4 424/4885PTGER2 405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.